203 related articles for article (PubMed ID: 29714141)
21. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
22. Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model.
Kovacs E
ScientificWorldJournal; 2006 Aug; 6():888-98. PubMed ID: 16892169
[TBL] [Abstract][Full Text] [Related]
23. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
Fu S; Chen X; Lo HW; Lin J
Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
Xu S; Grande F; Garofalo A; Neamati N
Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726
[TBL] [Abstract][Full Text] [Related]
25. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
[TBL] [Abstract][Full Text] [Related]
26. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.
Heo TH; Wahler J; Suh N
Oncotarget; 2016 Mar; 7(13):15460-73. PubMed ID: 26840088
[TBL] [Abstract][Full Text] [Related]
27. TRAF2 and TRAF5 associated with the signal transducing receptor gp130 limit IL-6-driven transphosphorylation of JAK1 through the inhibition of proximal JAK-JAK interaction.
Kimura M; Nagashima H; Okuyama Y; Ishii N; So T
Int Immunol; 2018 Jun; 30(7):291-299. PubMed ID: 29668931
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista.
Shi W; Yan D; Zhao C; Xiao M; Wang Y; Ma H; Liu T; Qin H; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
Biochem Biophys Res Commun; 2017 Sep; 491(1):159-165. PubMed ID: 28711499
[TBL] [Abstract][Full Text] [Related]
29. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130.
Hong SS; Choi JH; Lee SY; Park YH; Park KY; Lee JY; Kim J; Gajulapati V; Goo JI; Singh S; Lee K; Kim YK; Im SH; Ahn SH; Rose-John S; Heo TH; Choi Y
J Immunol; 2015 Jul; 195(1):237-45. PubMed ID: 26026064
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells.
Nagathihalli NS; Castellanos JA; VanSaun MN; Dai X; Ambrose M; Guo Q; Xiong Y; Merchant NB
Oncotarget; 2016 Oct; 7(40):65982-65992. PubMed ID: 27602757
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer.
Suzuki H; Mitsunaga S; Ikeda M; Aoyama T; Yoshizawa K; Yamaguchi M; Suzuki M; Narita M; Kawasaki T; Ochiai A
Cancer Med; 2022 Dec; 11(24):5001-5012. PubMed ID: 35578571
[TBL] [Abstract][Full Text] [Related]
32. STAT3 can be activated through paracrine signaling in breast epithelial cells.
Lieblein JC; Ball S; Hutzen B; Sasser AK; Lin HJ; Huang TH; Hall BM; Lin J
BMC Cancer; 2008 Oct; 8():302. PubMed ID: 18939993
[TBL] [Abstract][Full Text] [Related]
33. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets.
Majka M; Ratajczak J; Villaire G; Kubiczek K; Marquez LA; Janowska-Wieczorek A; Ratajczak MZ
Exp Hematol; 2002 Jul; 30(7):751-60. PubMed ID: 12135673
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases.
Hausherr A; Tavares R; Schäffer M; Obermeier A; Miksch C; Mitina O; Ellwart J; Hallek M; Krause G
Oncogene; 2007 Jul; 26(34):4987-98. PubMed ID: 17310994
[TBL] [Abstract][Full Text] [Related]
35. Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation.
Chen W; Yuan H; Cao W; Wang T; Chen W; Yu H; Fu Y; Jiang B; Zhou H; Guo H; Zhao X
Theranostics; 2019; 9(14):3980-3991. PubMed ID: 31281526
[No Abstract] [Full Text] [Related]
36. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling.
Huo Y; Yang J; Zheng J; Xu D; Yang M; Tao L; Yao H; Fu X; Yang J; Liu D; Hua R; Zhang J; Sun Y; Hu L; Liu W
Cell Prolif; 2022 May; 55(5):e13237. PubMed ID: 35487760
[TBL] [Abstract][Full Text] [Related]
37. IL-6/gp130/STAT3 signaling contributed to the activation of the PERK arm of the unfolded protein response in response to chronic β-adrenergic stimulation.
Men L; Guo J; Cao Y; Huang B; Wang Q; Huo S; Wang M; Peng D; Peng L; Shi W; Li S; Lin L; Lv J
Free Radic Biol Med; 2023 Aug; 205():163-174. PubMed ID: 37307935
[TBL] [Abstract][Full Text] [Related]
38. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
39. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3.
Greenhill CJ; Rose-John S; Lissilaa R; Ferlin W; Ernst M; Hertzog PJ; Mansell A; Jenkins BJ
J Immunol; 2011 Jan; 186(2):1199-208. PubMed ID: 21148800
[TBL] [Abstract][Full Text] [Related]
40. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
